The cost-effectiveness of belimumab and voclosporin for patients with Lupus Nephritis in the United States

Mandrik, O. orcid.org/0000-0003-3755-3031, Fotheringham, J., Ren, S. orcid.org/0000-0003-3568-7124 et al. (7 more authors) (2022) The cost-effectiveness of belimumab and voclosporin for patients with Lupus Nephritis in the United States. Clinical Journal of the American Society of Nephrology, 17 (3). pp. 385-394. ISSN 1555-9041

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2022 by the American Society of Nephrology. This is an author-produced version of a paper subsequently published in Clinical Journal of the American Society of Nephrology. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: lupus nephritis; economic analysis; United States; voclosporin; belimumab; cyclophosphamide; mycophenolate; cost-effectiveness; analysis
Dates:
  • Accepted: 12 January 2021
  • Published (online): 7 March 2022
  • Published: March 2022
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Academic Unit of Medical Education (Sheffield)
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Funding Information:
FunderGrant number
INSTITUTE FOR CLINICAL AND ECONOMIC REVIEWnan
Depositing User: Symplectic Sheffield
Date Deposited: 18 Mar 2022 14:29
Last Modified: 18 Mar 2022 16:47
Status: Published
Publisher: American Society of Nephrology (ASN)
Refereed: Yes
Identification Number: https://doi.org/10.2215/cjn.13030921
Related URLs:

Share / Export

Statistics